PRKACA Antibody

What are the optimal sample types for PRKACA antibody applications?

PRKACA antibodies have demonstrated reliable reactivity with multiple sample types across mammalian species. For Western blot applications, these antibodies show consistent detection in human cell lines (HeLa, LNCaP, HepG2, Jurkat, and K-562), mouse cell lines (Neuro-2a and NIH/3T3), and rat cell lines (HSC-T6 and SH-SY5Y) . For tissue samples, PRKACA antibodies have been validated on human breast cancer tissue, prostate cancer tissue, testis tissue, and heart tissue for immunohistochemistry applications . Mouse and rat testis tissues have also been successfully used for Western blot detection . When selecting sample types, consider that PRKACA expression levels may vary between tissues and cell types, which could affect detection sensitivity. For researchers beginning PRKACA studies, HeLa cells represent an excellent starting point as they consistently demonstrate robust PRKACA expression across multiple antibody validations.

What dilutions should be used for different experimental applications?

The optimal dilution of PRKACA antibodies varies depending on the specific application and the antibody clone being used. For Western blot applications, the recommended dilution ranges from 1:500-1:2000 for antibody 24503-1-AP and 1:1000-1:6000 for antibodies 27398-1-AP and 67491-1-Ig . For immunohistochemistry applications, the recommended dilution ranges from 1:50-1:500 for antibodies 24503-1-AP and 27398-1-AP, while a higher dilution range of 1:500-1:2000 is recommended for antibody 67491-1-Ig . When performing immunofluorescence, a dilution range of 1:50-1:500 is recommended for antibody 27398-1-AP . For immunoprecipitation experiments, 0.5-4.0 μg of antibody 27398-1-AP is recommended for 1.0-3.0 mg of total protein lysate . It is important to note that these are general recommendations, and researchers should perform titration experiments to determine the optimal dilution for their specific experimental conditions and sample types.

How should PRKACA antibodies be stored for maximum stability and performance?

PRKACA antibodies require proper storage conditions to maintain their activity and specificity. The recommended storage temperature for these antibodies is -20°C, where they remain stable for one year after shipment . The antibodies are typically supplied in a storage buffer consisting of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . This formulation helps maintain antibody stability during freeze-thaw cycles. For smaller volume antibodies (20 μl sizes), the formulation often contains 0.1% BSA as an additional stabilizing agent . Aliquoting is generally unnecessary for -20°C storage according to the manufacturer's recommendations . Repeated freeze-thaw cycles should still be avoided to prevent potential degradation of antibody quality. When handling these antibodies, it is advisable to keep them on ice during experimental procedures and return them to -20°C storage promptly after use to maximize their longevity and performance.

What positive controls should be used to validate PRKACA antibody specificity?

When validating PRKACA antibody specificity, several well-characterized positive controls have been established through extensive testing. For Western blot applications, HeLa cells, Neuro-2a cells, and SH-SY5Y cells consistently demonstrate reliable PRKACA expression and can serve as excellent positive controls . For tissue-based applications, human breast cancer tissue and human testis tissue have been validated as positive controls for immunohistochemistry . For immunoprecipitation experiments, HeLa cells have been verified as suitable positive controls . When performing immunofluorescence, U2OS cells provide reliable positive staining . The expected molecular weight for PRKACA detection is 38-43 kDa, with a calculated molecular weight of 41 kDa . Researchers should also consider using knockout or knockdown systems as negative controls to further validate antibody specificity. Multiple publications have utilized PRKACA knockout mouse samples to validate antibody specificity, particularly with antibodies from Cell Signaling Technology (4782) and BD Biosciences (610127, 610085, and 610107) .

How can cross-reactivity with other protein kinase isoforms be assessed and minimized?

Cross-reactivity with related protein kinase isoforms represents a significant challenge when working with PRKACA antibodies. To assess potential cross-reactivity, researchers should first examine the immunogen sequence used to generate the antibody. The 24503-1-AP antibody was generated using PRKACA fusion protein Ag21478, while the 27398-1-AP antibody used PRKACA fusion protein Ag26392 . Comparing these sequences against other protein kinase catalytic subunits can identify regions of homology that might lead to cross-reactivity. Practical validation should include side-by-side testing with recombinant PRKACA, PRKACB, and PRKACG proteins in Western blot applications. Additionally, PRKACA knockout validation has been performed for several antibodies, including those from Cell Signaling Technology and BD Biosciences, providing strong evidence for specificity . When cross-reactivity is observed, it can be minimized by using higher antibody dilutions, more stringent washing conditions, or pre-absorption with recombinant proteins containing the cross-reactive epitopes. Researchers should also consider using multiple antibodies targeting different epitopes of PRKACA to confirm their findings.

What are the critical factors for successful PRKACA detection in immunohistochemistry?

Successful immunohistochemical detection of PRKACA requires careful attention to several critical factors. Antigen retrieval methods significantly impact staining quality, with manufacturers recommending TE buffer pH 9.0 as the primary method, while citrate buffer pH 6.0 serves as an alternative . The tissue fixation process must balance preserving tissue morphology while maintaining epitope accessibility; 10% neutral-buffered formalin fixation for 24-48 hours provides optimal results for most applications. Blocking conditions require careful optimization, with 5-10% normal serum from the same species as the secondary antibody effectively reducing background. Antibody concentration and incubation time significantly impact signal-to-noise ratio, with overnight incubation at 4°C generally yielding more specific staining than shorter incubations at room temperature. Signal amplification systems should be selected based on expression levels, with avidin-biotin complexes or tyramide signal amplification recommended for low-expressing samples. Detection systems must be appropriate for the primary antibody species, with horseradish peroxidase-conjugated secondary antibodies and DAB substrate providing excellent sensitivity and stability for permanent sections. Counterstaining with hematoxylin at appropriate dilution ensures nuclear visualization without obscuring PRKACA signals.

How can phosphorylation status influence PRKACA antibody recognition?

The phosphorylation status of PRKACA can significantly impact antibody recognition and experimental outcomes. PRKACA contains multiple phosphorylation sites, including threonine-197 and serine-338, which undergo dynamic modification during activation and regulation . These post-translational modifications can alter protein conformation, potentially masking or exposing epitopes recognized by specific antibodies. Researchers should determine whether their antibody recognizes total PRKACA or preferentially binds to specific phosphorylated forms by consulting the immunogen information. The antibodies 24503-1-AP and 27398-1-AP, generated against fusion proteins Ag21478 and Ag26392 respectively, likely detect total PRKACA regardless of phosphorylation state . For experiments requiring distinction between phosphorylated and non-phosphorylated forms, phosphatase treatment of samples prior to Western blotting can help establish baseline detection. Conversely, treatments that enhance phosphorylation, such as forskolin or dibutyryl-cAMP, can be used to increase phosphorylated forms. When interpreting conflicting results between different antibodies, researchers should consider whether phosphorylation-dependent epitope recognition might explain the discrepancies. For studies specifically focused on PRKACA activation, using antibodies that distinguish between phosphorylated and non-phosphorylated forms can provide valuable insights into signaling dynamics.

What strategies exist for multiplexing PRKACA detection with other proteins of interest?

Multiplexed detection of PRKACA alongside other proteins enables comprehensive analysis of signaling networks and protein interactions. For fluorescence-based multiplexing in immunohistochemistry or immunofluorescence, researchers should select PRKACA antibodies from different host species than other target antibodies to enable species-specific secondary antibody detection . When this is not possible, directly conjugated primary antibodies can circumvent cross-reactivity issues. For Western blot multiplexing, sequential probing with stripping between antibodies works well for proteins with distinct molecular weights, though incomplete stripping may compromise subsequent detection. Alternatively, parallel blotting of the same samples on multiple membranes offers higher reliability but requires more sample. Fluorescent Western blotting using differentially labeled secondary antibodies enables simultaneous detection of multiple proteins, with the PRKACA expected molecular weight range of 38-43 kDa allowing differentiation from many interaction partners . For co-immunoprecipitation studies investigating PRKACA binding partners, the 27398-1-AP antibody has been validated for immunoprecipitation applications . Proximity ligation assays represent an advanced technique for visualizing PRKACA interactions with spatial resolution in situ, though this requires careful antibody validation to ensure specificity.

Why might Western blot detection of PRKACA show multiple bands?

Multiple bands in PRKACA Western blots can result from several biological and technical factors that require systematic investigation. PRKACA undergoes post-translational modifications including phosphorylation and myristoylation, which can alter protein mobility during electrophoresis . While the calculated molecular weight of PRKACA is 41 kDa, the observed molecular weight ranges from 38-43 kDa, which likely reflects these modifications . Alternative splicing produces multiple PRKACA isoforms, including variants affecting the N-terminal domain which can manifest as distinct bands. Sample preparation conditions significantly impact results, with insufficient denaturation leading to incompletely reduced protein complexes appearing as higher molecular weight bands. Proteolytic degradation during sample handling can generate lower molecular weight fragments, preventable by using fresh protease inhibitors and maintaining cold temperatures throughout processing. Non-specific binding may occur particularly at lower antibody dilutions, so testing multiple dilutions within the recommended range (1:500-1:6000) can identify optimal conditions . Cross-reactivity with related proteins, especially other PKA catalytic subunits, might occur due to sequence homology, addressable by using knockout validation approaches as demonstrated with several PRKACA antibodies .

How can background staining be reduced in PRKACA immunohistochemistry?

Excessive background staining in PRKACA immunohistochemistry can significantly compromise result interpretation but can be addressed through systematic optimization. Antibody concentration requires careful titration, with the recommended dilution ranges of 1:50-1:500 for antibodies 24503-1-AP and 27398-1-AP, and 1:500-1:2000 for antibody 67491-1-Ig serving as starting points . Blocking protocols should be enhanced using 3-5% BSA or 5-10% normal serum from the secondary antibody species, with extended blocking times of 1-2 hours at room temperature. Washing steps should be increased in both duration and frequency, using PBST (PBS with 0.1-0.3% Tween-20) for more effective removal of unbound antibodies. Endogenous peroxidase activity, particularly prominent in tissues like liver and kidney, requires thorough quenching with 0.3-3% hydrogen peroxide for 10-30 minutes before antibody application. Endogenous biotin can cause significant background when using avidin-biotin detection systems, necessitating an avidin-biotin blocking step when these detection methods are employed. Antigen retrieval conditions should be optimized, comparing the recommended TE buffer pH 9.0 against citrate buffer pH 6.0 to determine which provides the best signal-to-noise ratio for specific tissue types . Secondary antibody cross-reactivity can be reduced by using highly cross-adsorbed secondary antibodies specifically tested against the species being examined.

What factors might cause inconsistent results between different PRKACA antibody clones?

Inconsistent results between different PRKACA antibody clones represent a significant challenge in research reproducibility but can be systematically analyzed and addressed. Epitope differences are the primary cause of discrepancy, as antibodies targeting distinct regions of PRKACA may be differentially affected by protein conformation, post-translational modifications, protein-protein interactions, or epitope masking . Antibody format variations between polyclonal (24503-1-AP, 27398-1-AP) and monoclonal antibodies affect detection patterns, with polyclonals recognizing multiple epitopes providing robust detection but potentially higher background, while monoclonals offer higher specificity but may be more sensitive to epitope modifications . Protocol optimization requirements differ between antibodies, with variables including antigen retrieval methods (TE buffer pH 9.0 versus citrate buffer pH 6.0), incubation times, and detection systems needing independent optimization for each antibody . Sample preparation variations impact results, with different fixation methods, buffer compositions, or detergent concentrations potentially exposing or masking epitopes differentially. Cross-reactivity profiles vary between antibodies, with each potentially recognizing different sets of non-target proteins, necessitating validation through knockout controls as demonstrated for several PRKACA antibodies . Antibody quality and batch variation can occur, particularly with polyclonal antibodies where each production lot contains a unique antibody mixture.

How should conflicting PRKACA localization data be interpreted and resolved?

Conflicting data regarding PRKACA subcellular localization can arise from both technical and biological factors. PRKACA dynamically shuttles between cytoplasmic and nuclear compartments in response to various stimuli, and capturing this dynamic process requires careful experimental design . Cell type-specific localization patterns exist, with PRKACA distribution varying between cell types like HeLa, U2OS, and Neuro-2a cells that have been validated for PRKACA antibody applications . Activation state significantly impacts localization, as cAMP binding to regulatory subunits releases catalytic subunits, enabling nuclear translocation; researchers should standardize cell treatment conditions to control this variable. Fixation and permeabilization methods critically affect epitope accessibility and preservation of subcellular structures, with cross-linking fixatives like paraformaldehyde potentially masking epitopes accessible with methanol fixation. Antibody clone selection matters significantly, as different antibodies (24503-1-AP, 27398-1-AP, 67491-1-Ig) may preferentially recognize distinct pools of PRKACA based on their epitope specificity and accessibility . Technical detection limitations, including microscope resolution, signal amplification methods, and detection thresholds, may reveal different aspects of PRKACA distribution. To resolve discrepancies, researchers should implement complementary approaches including subcellular fractionation followed by Western blotting, live-cell imaging with fluorescently tagged PRKACA, and super-resolution microscopy techniques to provide multi-dimensional verification of localization patterns.

How do PRKACA gene mutations and amplifications affect antibody detection?

PRKACA mutations and amplifications present unique challenges for antibody-based detection that researchers must consider when studying disease models. Germline PRKACA amplifications have been identified in patients with various forms of adrenocortical hyperplasia, including pigmented nodular adrenocortical disease (PPNAD), non-pigmented isolated micronodular adrenocortical disease (iMAD), and primary macronodular adrenocortical hyperplasia (PMAH) . These amplifications create dosage effects that may alter quantitative Western blot results, with higher expression levels potentially leading to signal saturation or non-linear detection responses. Mutation-specific conformational changes can significantly impact epitope accessibility, particularly with antibodies targeting regions affected by known pathogenic mutations. Researchers should verify whether their antibodies (such as 24503-1-AP, 27398-1-AP, or 67491-1-Ig) recognize epitopes within commonly mutated regions . Fusion proteins resulting from chromosomal rearrangements, though not specifically mentioned in the search results for PRKACA, could create chimeric proteins that might be detected differently by antibodies targeting different regions of the protein. When studying patient samples with known PRKACA alterations, researchers should consider using multiple antibodies targeting different epitopes to ensure comprehensive detection and characterization of potentially altered PRKACA proteins.

What experimental approaches can distinguish between PRKACA isoforms?

Distinguishing between PRKACA isoforms requires carefully designed experimental approaches that exploit their structural and functional differences. RT-PCR using isoform-specific primers targeting unique exon junctions provides the most direct method for distinguishing isoform expression at the mRNA level, establishing which variants are transcribed in the tissue or cells of interest. Western blotting with gradient gels (10-15% acrylamide) can resolve small molecular weight differences between isoforms, with the observed molecular weight range of 38-43 kDa for PRKACA potentially representing different isoforms . Isoform-specific antibodies, though not explicitly described in the search results, would ideally target unique epitopes present in only one isoform; researchers should carefully review immunogen sequences of available antibodies (24503-1-AP, 27398-1-AP) to determine potential isoform specificity . Two-dimensional gel electrophoresis separates isoforms based on both molecular weight and isoelectric point, providing enhanced resolution of post-translationally modified variants. Mass spectrometry analysis of immunoprecipitated PRKACA (using antibody 27398-1-AP validated for IP) can identify peptide sequences unique to specific isoforms . Functional assays measuring kinase activity under isoform-selective conditions can complement immunological detection methods to validate the presence of specific active isoforms.

How can PRKACA be effectively studied in complex with its regulatory subunits?

Investigating PRKACA in complex with its regulatory subunits requires techniques that preserve native protein interactions while enabling specific detection. Co-immunoprecipitation using antibody 27398-1-AP, which has been validated for immunoprecipitation applications, can pull down PRKACA along with bound regulatory subunits from cell lysates under native conditions . The immunoprecipitated complexes can then be analyzed by Western blotting for both PRKACA (38-43 kDa) and associated regulatory subunits. Proximity ligation assays in fixed cells or tissues can visualize PRKACA-regulatory subunit interactions with spatial resolution, detecting interactions only when the proteins are within 40 nm of each other. Fluorescence resonance energy transfer (FRET) using fluorescently tagged PRKACA and regulatory subunits enables real-time monitoring of interactions in living cells, with decreased FRET signal upon cAMP-induced dissociation. Size exclusion chromatography of native cell lysates followed by Western blot analysis with PRKACA antibodies (24503-1-AP, 27398-1-AP, or 67491-1-Ig) can separate and identify different PRKACA-containing complexes based on their molecular size . Crosslinking mass spectrometry can identify specific interaction interfaces between PRKACA and its regulatory partners, providing structural insights into complex formation. Blue native PAGE maintains protein complexes during electrophoresis, allowing subsequent Western blotting to identify PRKACA-containing complexes of different compositions.

What considerations are important when studying PRKACA in cancer models?

Studying PRKACA in cancer models requires consideration of several cancer-specific factors that may affect detection and interpretation. Expression level heterogeneity between and within tumors necessitates careful sampling strategies and quantitative analysis methods when applying PRKACA antibodies to cancer tissues . Multiple validated antibodies (24503-1-AP, 27398-1-AP, 67491-1-Ig) have been tested on cancer samples including human breast cancer and prostate cancer tissues, providing researchers with options for cancer studies . Genetic alterations in cancer may include PRKACA amplifications similar to those observed in adrenocortical diseases, potentially affecting quantitative comparisons between samples . These amplifications may necessitate adjusted antibody dilutions from the standard recommended ranges (1:500-1:2000 for WB; 1:50-1:500 for IHC) to prevent signal saturation in high-expressing samples . Tumor microenvironment factors including hypoxia, inflammation, and altered pH can influence PRKACA regulation, localization, and post-translational modifications, potentially affecting epitope accessibility and antibody recognition. Treatment-induced changes in PRKACA expression or activity should be monitored using consistent protocols, as therapeutic interventions may alter PRKACA biology in ways that affect antibody-based detection methods. When designing immunohistochemistry experiments on cancer tissues, researchers should include appropriate controls and consider the validated antibody applications on cancer tissues, such as human breast cancer tissue staining with antibodies 24503-1-AP and 67491-1-Ig .

How should PRKACA knockout or knockdown validation be designed and interpreted?

Proper design and interpretation of PRKACA knockout or knockdown validation experiments are essential for confirming antibody specificity and biological findings. For knockdown approaches, siRNA or shRNA targeting PRKACA should include at least three distinct targeting sequences to minimize off-target effects, with scrambled non-targeting sequences serving as negative controls. Knockout validation has been successfully implemented with PRKACA antibodies from Cell Signaling Technology and BD Biosciences, providing a gold standard for antibody specificity assessment . CRISPR-Cas9 knockout design should target early exons to ensure complete protein elimination, with careful screening for off-target effects through whole-genome sequencing or predicted off-target site analysis. Validation timing is critical as acute and chronic PRKACA depletion may trigger different compensatory mechanisms, potentially including upregulation of PRKACB or PRKACG isoforms that might cross-react with some antibodies. Quantification methods must be standardized across experiments, with Western blot analysis demonstrating at least 80-90% reduction in the correct molecular weight band (38-43 kDa) for knockdown validation . Multiple detection methods should be employed, using different PRKACA antibodies (24503-1-AP, 27398-1-AP, 67491-1-Ig) targeting distinct epitopes to comprehensively confirm knockdown or knockout efficiency . Functional validation through PKA activity assays complements immunological detection, confirming that reduced protein levels correlate with decreased catalytic activity.

What approaches enable quantitative analysis of PRKACA expression levels?

Accurate quantification of PRKACA expression requires specialized approaches that account for technical variables while maintaining biological relevance. Western blot quantification should employ internal loading controls such as housekeeping proteins (GAPDH, β-actin) or total protein staining (Ponceau S, SYPRO Ruby) to normalize PRKACA signals between samples. The linear detection range must be established through serial dilutions of positive control samples (HeLa, Neuro-2a, SH-SY5Y cells) to ensure quantification occurs within this range . Quantitative PCR with validated PRKACA-specific primers provides mRNA-level quantification, though this should be complemented with protein-level analysis due to potential post-transcriptional regulation. ELISA-based approaches using PRKACA antibodies as capture and detection reagents can provide absolute quantification when calibrated against recombinant PRKACA standards. Mass spectrometry-based approaches, particularly selected reaction monitoring (SRM) or parallel reaction monitoring (PRM), enable absolute quantification of PRKACA with high specificity by targeting unique peptide sequences. Immunohistochemistry quantification requires digital image analysis with consistent acquisition parameters, using methods such as H-score or Allred scoring systems to integrate staining intensity and percentage of positive cells. Flow cytometry for intracellular PRKACA staining enables single-cell quantification across populations, revealing heterogeneity that might be masked in bulk analyses.

What are the critical controls for studying PRKACA phosphorylation targets?

Studying PRKACA phosphorylation targets requires rigorous controls to establish specificity and biological relevance. Pharmacological manipulation using specific PKA activators (forskolin, dibutyryl-cAMP) and inhibitors (H-89, PKI peptide) should demonstrate dose-dependent effects on substrate phosphorylation, confirming PRKACA dependence. PRKACA knockdown or knockout validation, successfully employed with antibodies from Cell Signaling Technology and BD Biosciences, provides genetic evidence for PRKACA-dependent phosphorylation events . Phospho-specific antibodies against substrates must be validated with phosphatase treatment controls to confirm specificity for the phosphorylated form. Site-directed mutagenesis of target phosphorylation sites (serine/threonine to alanine) should abolish detection by phospho-specific antibodies and functional responses dependent on phosphorylation. In vitro kinase assays with purified PRKACA and potential substrates provide direct evidence of phosphorylation capability, complementing cellular studies. Temporal dynamics analysis following PKA activation should reveal phosphorylation kinetics consistent with direct PRKACA targets rather than downstream effects. Specificity across PKA isoforms can be assessed through selective knockdown of PRKACA versus PRKACB or PRKACG, determining whether substrate phosphorylation is specifically PRKACA-dependent. Subcellular localization studies using fractionation followed by Western blotting with PRKACA antibodies (24503-1-AP, 27398-1-AP, 67491-1-Ig) can reveal compartmentalization of PRKACA relative to its substrates .

How can PRKACA antibodies be utilized in clinical tissue microarrays?

The application of PRKACA antibodies to clinical tissue microarrays requires specific optimizations to ensure reliable and interpretable results. Preanalytical variables including fixation time, tissue processing, and antigen retrieval methods must be standardized across all samples, with the recommended TE buffer pH 9.0 or alternative citrate buffer pH 6.0 protocols validated for consistent results . Antibody selection should prioritize those with demonstrated specificity in immunohistochemistry applications on relevant tissues, such as 24503-1-AP (validated on human breast cancer tissue), 27398-1-AP (validated on human testis and heart tissue), and 67491-1-Ig (validated on human breast cancer and prostate cancer tissue) . Titration experiments are essential to determine optimal dilution ranges for specific microarray parameters, starting with manufacturer recommendations (1:50-1:500 for 24503-1-AP and 27398-1-AP; 1:500-1:2000 for 67491-1-Ig) but adjusting based on specific tissue types and detection systems . Control tissues should include both positive controls (tissues known to express PRKACA, such as testis and breast cancer) and negative controls (antibody diluent without primary antibody) on each microarray slide. Scoring systems must be established before analysis, with clearly defined criteria for positive staining including intensity thresholds, subcellular localization parameters, and percentage cutoffs for positive cells. Inter-observer validation between multiple pathologists ensures reproducible interpretation, calculating kappa statistics to quantify agreement levels. Correlation with clinical data requires rigorous statistical approaches accounting for multiple comparisons when assessing associations between PRKACA expression and patient outcomes.